---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-126265"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2022-12-12T23:59:59+00:00"
generated_at: "2026-06-21T06:23:25.716460+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# JATT grants Eli Lilly 550,000 shares for IL-33 license; contingent on Zura merger

## Summary
- JATT granted Eli Lilly 550,000 Class A shares as partial consideration for Lilly licensing an IL-33 compound to Z33, a Zura subsidiary.
- Shares issued in a private placement exempt from registration under Section 4(a)(2) of the Securities Act.
- Shares subject to staggered lock-up: one-third restricted for 6, 12, and 24 months post-closing, with early release if stock hits $12 for 20 of 30 trading days.
- Equity Grant closing contingent on completion of JATT's business combination with Zura Bio.
- Lilly entered into a License Agreement with Z33 on December 8, 2022 for the compound.

## SEC filing metadata
- accession: 0001104659-22-126265
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2022-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465922126265/0001104659-22-126265-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465922126265/tm2232433d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-126265
- JSON: https://secwatch.observer/filing/0001104659-22-126265.json
- Plain text: https://secwatch.observer/filing/0001104659-22-126265.txt

## Key facts
- Material Agreements
  Zura Bio Ltd entered into Equity Grant Agreement with Eli Lilly and Company valued at JATT to issue and grant to Lilly 550,000 Class A ordinary shares in a private placement transaction (effective 2022-12-08).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Eli Lilly and Company
  - Value: JATT to issue and grant to Lilly 550,000 Class A ordinary shares in a private placement transaction
  - Effective: 2022-12-08
  source text: Concurrently with the execution of the License Agreement, on December 8, 2022, as partial consideration for Lilly entering into the License Agreement with Z33, JATT and Lilly entered into that certain Equity Grant Agreement, pursuant to which JATT agreed to issue and grant to Lilly 550,000 Class A ordinary shares of JATT (the “ Shares ”) in a private placement transaction.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465922126265/0001104659-22-126265-index.htm
- Material Agreements
  Zura Bio Ltd entered into License, Development and Commercialization Agreement with Eli Lilly and Company valued at License granted regarding intellectual property rights for a certain compound relating to IL-33 (effective 2022-12-08).
  - Action: entry
  - Agreement: license
  - Counterparty: Eli Lilly and Company
  - Value: License granted regarding intellectual property rights for a certain compound relating to IL-33
  - Effective: 2022-12-08
  source text: Effective on December 8, 2022, Z33 Bio Inc. (“ Z33 ”), an entity controlled by Zura entered into the License, Development and Commercialization Agreement (the “ License Agreement ”) with Eli Lilly and Company (“ Lilly ”), pursuant to which Lilly granted a license to Z33 regarding certain intellectual property rights for a certain compound relating to IL-33 to develop, manufacture and commercialize such compound, subject to the terms and conditions set forth therein.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465922126265/0001104659-22-126265-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.